Back to Treatments

Treatment

Pembrolizumab (Immunotherapy)

3
Conditions
81
Trials
75K
Participants
52%
Average Safety

Condition Evidence

Breast cancer

72 trials · 20K participants

55% effectiveness · 40% safety

Larynx cancer

7 trials · 15K participants

60% effectiveness · 55% safety

Lip and oral cavity cancer

2 trials · 40K participants

75% effectiveness · 60% safety
Pembrolizumab (Immunotherapy) | DFDA